

TO OUR STAKEHOLDERS

Gastro-Intestinal Cancer Institute NZ

PO Box 28 723

Remuera

Auckland 1541

Tel 0800 112 775

www.gicinz.org.nz



ANNUAL REPORT

FY 2015-2016

The Gastro-Intestinal Cancer Institute of New Zealand (GICI) is dedicated to improving the outcomes for patients with gastro-intestinal cancer. GICI aims to increase awareness of GI cancers and raise funds to support clinical research in New Zealand, focusing particularly on clinical trials.

TO OUR STAKEHOLDERS

CHAIR'S REPORT

GICI has had a significant increase in profile and fundraising activities over the last year. We launched our new brand in March at the Kelliher Trust in Parnell. Resources have been distributed around New Zealand through various forms of media including the backs of buses! General practitioners and medical specialists have received print media for waiting rooms. This brings GICI into a new era with increased engagement across all sectors.

On the back of the 'Awareness Campaign' we also prepared for the launch of the 'Dine In for GICI' and co-ordination of two events in the new financial year. Donations have also resulted from Lions Clubs across New Zealand. This is supported by the new GICI pamphlet and Donate to GICI pamphlet.

Events on behalf have profiled this last year with 'SuperCars for a Super Cause' run by Bayley's Capital in Wellington raising \$103,000. Another successful event was 'Raising it for Hilz'. Peer to peer fundraising continues to occur.

To further improve our income we have partnered with Perpetual Guardian and the Hugh Green Foundation who have generously supported us with grants and are willing to continue with a partnership.

In 2015, GICI began funding the 'Circulating Tumour DNA as a Biomarker of Pancreatic Cancer' which has the capacity to improve the understanding of who had the best chances of survival with surgery. Initial outcomes for the SCOT and A LaCART trials have been released with promising outcomes.



I would like to personally acknowledge all of the GICI board, the Scientific Advisory Committee and Ruth Davy for their excellent efforts this year. To all who have donated and supported us we thank you and look forward to working with you over the next year. A very special mention to our corporate partner Bayley's Capital who went above and beyond for us in Wellington.

A handwritten signature in black ink, appearing to read 'G Baker', written in a cursive style.

Grant Baker, Chairperson and Cancer Survivor.

TO OUR STAKEHOLDERS

STRATEGIC HIGHLIGHTS

The year has been a busy one for GICI NZ with many new strategies in progress:

- Launch of the new Awareness Campaign with an engaging brand
- Development of the Dine In for GICI
- Engagement and partnership with Perpetual Guardian and the Hugh Green Foundation
- Approval of a GI Cancer Research Fellowship over a three year period through a grant from the Hugh Green Foundation
- An GI Cancer Clinical Research Expression of Interest was approved by the GICI board for circulation
- Improved systems to ensure optimal outcomes
- Increased the opportunity for donations and bequests through increased community engagement

LAUNCH OF THE AWARENESS CAMPAIGN

A social and printed media awareness campaign was launched at Kelliher Trust rooms in Parnell on March 16, 2016 with approximately fifty key people in attendance. A new 'edgy' engaging image with the key message 'Not to be Ignored' was profiled across New Zealand through print media, radio advertising and guest presentations at service clubs in Auckland. Several national media releases with personal stories, pamphlets delivered through NZ Doctor to each general practitioner, billboards across the back of five buses across Auckland for a month all occurred. Increased social media and a video demonstrating the making of the imagery occurred with engagement of over 190,000 people. Radio and TV engagement was promoted through the use of a PR agency with some engagement. Two magazine articles resulted, one being MindFood.



TO OUR STAKEHOLDERS

KELLIHER TRUST EVENT



DINE IN FOR GICI



A new strategy to ensure 'events of behalf' and provide a fundraising stream for GICI has enabled engagement of two Dine In's in the next financial year. Systems to ensure optimal outcomes are being put in place for promotion and to ensure capture of all relevant data. Supported by ECOYA, each Dine In host receives a candle to thank them for their efforts.



TO OUR STAKEHOLDERS

INCREASED CORPORATE ENGAGEMENT

Both Perpetual Guardian and the Hugh Green Foundation have supported the Awareness Campaign through funding grants for which we are very grateful. Novartis also supported the development and circulation of our new donation and 'Not to be Ignored' pamphlets.



As part of the new strategic direction GICI requires a relationship with key funders to access new funding streams and support. This has been achieved by working with Perpetual Guardian and aligning with their new Perpetual Guardian Foundation. Investment in the Foundation will allow the organisation to establish a long term investment strategy to secure guaranteed funds for clinical research trials.



HUGH GREEN FOUNDATION

The Hugh Green Foundation, as well as funding the Awareness Campaign, approved our application for a part time Gastro-Intestinal Cancer Research Fellowship. The rationale for keeping the fellowship as a part time position is that it allows those needing to continue practising as clinicians, such as medical registrars or junior specialists, the opportunity to engage in vital clinically-linked research. The appointment will be at 0.3-0.5 FTE for a period of 1-3 years.

The GI Cancer Clinical Fellowship will be available in (but not limited to) the speciality areas of cancer surgery, radiation oncology, medical oncology, palliative care, cancer genetics, radiology, anatomical pathology, nutrition, psychiatry or public health.

GICI intends this position will be advertised nationwide and applicants from any region of New Zealand will be considered.

TO OUR STAKEHOLDERS

SCIENTIFIC ADVISORY COMMITTEE

The Scientific Advisory Committee (SAC) offers advice to the GICI Board about clinical research into gastrointestinal cancers, and also provides guidance on all clinical matters for GICI. Our focus is on the entire gastrointestinal tract. The SAC assesses applications from New Zealand researchers for funding for clinical trials, and also searches for studies relevant for New Zealand which GICI could support, in an effort to make more trials available. This increases opportunities for patients with GI cancers to participate in trials of new therapies, and gain from them.

The SAC members offer a breadth of experience and expertise, with Professor Michael Findlay (Director Cancer Trials New Zealand), Assoc Professor Clare Wall (nutrition), Kerin Thompson (clinical trials), Professor John McCall and Professor Bridget Robinson (both with University research groups). In 2016, we have said farewell to Dr Chris Wynne, and are delighted that Dr Iain Ward, another radiation oncologist with a strong commitment to clinical trials, has joined the SAC. During 2016, GICI funding has supported a trial in locally advanced pancreatic cancer where response to treatment will be measured using circulating tumour derived DNA (ctDNA). GICI has also supported the TOPGEAR study in gastric cancer, in conjunction with our Australian colleagues, and an initial report is expected soon. The results are starting to emerge for the GICI-supported surgical A La Cart study comparing laparoscopic surgery for rectal cancer with standard anterior resection, in collaboration with the Australasian Gastro-Intestinal Study Group (AGITG). However, we will need longer follow-up to show whether laparoscopic surgery is effective, and for which patient groups.



Bridget Robertson

Scientific Advisory Committee Chairperson

TO OUR STAKEHOLDERS

FUNDRAISING



The official handover of \$102,300 from Mark Hourigan of Bayleys' Capital Commercial, Glenn Peachey of Partridge Jewellers and Rick Armstrong of Armstrong Prestige. In October of 2015, Grant Baker transported four of his Ferrari cars to support Bayleys' Capital Commercial who hosted the first SuperCar for a Super Cause.

..... 23rd AUGUST 2015



In memory of the passing of Hiliary Bull from pancreatic cancer, Tony and Christine Bull hosted an event to raise funds for GICl at the Howick Lounge. Raising it for Hilz brought an amazing \$23,700. For Tony and Christine they found it be a very healing event surrounded by supportive friends and family.

These two excellent examples of 'events on behalf' acknowledge the efforts of the community we work with.

TO OUR STAKEHOLDERS

FINANCIAL HIGHLIGHTS

The fundraising income through events and donations remains very positive. Overall we are in a financially stable situation with funds invested.

OPERATING HIGHLIGHTS

Funds have been tagged for research trials, however distribution of funds has not occurred this year. The number of participants willing to participate in New Zealand trials dictates the use of the funds. Overheads remain very low thanks to Business Bakery and donation of services from Price Waterhouse Cooper.

LOOKING AHEAD

We are working towards increasing 'peer to peer' funding through the Everyday Hero website at present, however we are working towards a new fundraising system and CRM database with FrontStream. Used very effectively by the other large charities, it has the ability to provide ticketing for events, host Dine In for GICI and Get Gutsy for GICI to ensure more donor engagement and community participation.

The positioning of funds with an Endowment fund to build the capacity of GICI is a priority for 2015-2016. We have recommenced grant applications and are planning to access \$100K in the next financial year through grant funding.

The following accounts provide a statement of financial performance and the statement of financial position for 2015-2016. A full set of accounts are available on request.



Ruth Davy
Executive Officer
September 20, 2016

GI CANCER INSTITUTE (NZ) LIMITED ANNUAL REPORT

FOR THE YEAR ENDED 31 MARCH 2016

GI CANCER INSTITUTE (NZ) LIMITED STATEMENT OF FINANCIAL PERFORMANCE FOR THE YEAR ENDED 31 MARCH 2016

	Note	Actual* This Year \$	Actual* Last Year \$
Revenue	1		
Fundraising and event income		129,253	33,180
Grant income and donations		85,469	104,507
Interest, dividends and other investment revenue*		3,884	3,590
Total Revenue*		218,606	141,277
Expenses	2		
Expenses related to public fundraising*		42,516	12,879
Volunteer and employee related costs*	7	81,278	80,620
Grants and donations made*		-	7,826
Other expenses		3,282	2,110
Depreciation and amortisation		2,458	4,914
Total Expenses*		129,534	108,349
Surplus for the Year*		89,072	32,928

TO OUR STAKEHOLDERS

GI CANCER INSTITUTE (NZ) LIMITED STATEMENT OF FINANCIAL POSITION AS AT 31 MARCH 2016

	Note	Actual* This Year \$	Actual* Last Year \$
Assets			
Current Assets			
Bank accounts and cash*	3	277,398	184,740
Debtors and prepayments*	3	10,837	5,677
Total Current Assets		288,235	190,417
Non-Current Assets			
Property, plant and equipment*	3, 4	157	315
Intangible assets	3, 4	2,300	4,600
Total Non-Current Assets		2,457	4,915
Total Assets*		290,692	195,332
Liabilities			
Current Liabilities			
Creditors and accrued expenses*	3	13,631	3,489
Employee costs payable	3	8,546	7,700
Unused donations and grants with conditions*	3	-	4,700
		-	
Total Current Liabilities		22,177	15,889

TO OUR STAKEHOLDERS

Total Liabilities*		22,177	15,889
Total Assets less Total Liabilities (Net Assets)*		268,515	179,443
Accumulated Funds			
Capital contributed by owners or members*	5	-	-
Accumulated surpluses*	5	207,461	145,421
Reserves*	5,6	61,054	34,022
Total Accumulated Funds*		268,515	179,443



TO OUR STAKEHOLDERS

CONTACT INFORMATION

RUTH DAVY
EXECUTIVE OFFICER



Tel 027 273 7033
rdavy@gicin.org.nz

GRANT BAKER
CHAIRPERSON



Tel 021 729 800
grant@gbaker.co.nz

ORGANISATIONAL INFORMATION

CC Number: 39174

Gastro-Intestinal Cancer Institute NZ
PO Box 28723, Remuera, Auckland 1541, New Zealand

Tel 0800 112 775
www.gicin.org.nz

